申请人:RESEARCH & INNOVATION SOC. COOP.
A R.L.
公开号:EP1900365A2
公开(公告)日:2008-03-19
The present invention describes compounds deriving from chemical reactions between saturated or monounsaturated acyl derivatives and primary amines or primary alcohols that display specific cannabinoid-like pharmacological activity without exhibiting the central unwanted side effects typical of synthetic cannabinoids or endocannabinoids acting on central cannabinoid (CB1) receptors. These compounds, having this pharmacological activity, may be utilised to prevent or to treat pathological conditions and diseases in mammals, including human subjects, that may undergo a clinical improvement upon their administration.
本发明描述了由饱和或单不饱和酰基衍生物与伯胺或伯醇之间的化学反应所产生 的化合物,这些化合物显示出类似大麻素的特殊药理活性,而不会表现出合成大麻 素或作用于中枢大麻素(CB1)受体的内源性大麻素所特有的中枢性不良副作用。这些具有这种药理活性的化合物可用于预防或治疗哺乳动物(包括人类)的病理状况和疾病,服用后可改善临床症状。